RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Free Report) was the recipient of a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 417,400 shares, a growth of 23.1% from the July 15th total of 339,200 shares. Approximately 1.3% of the shares of the stock are sold short. Based on an average daily volume of 6,580,000 shares, the short-interest ratio is presently 0.1 days.
Analyst Upgrades and Downgrades
Separately, StockNews.com initiated coverage on RedHill Biopharma in a research report on Friday. They issued a “hold” rating for the company.
View Our Latest Stock Report on RedHill Biopharma
Institutional Investors Weigh In On RedHill Biopharma
RedHill Biopharma Stock Performance
RDHL traded down $0.08 during trading on Friday, reaching $0.29. The stock had a trading volume of 2,379,580 shares, compared to its average volume of 3,311,910. RedHill Biopharma has a 1-year low of $0.26 and a 1-year high of $3.28. The stock has a 50 day moving average of $0.40 and a two-hundred day moving average of $0.46.
Shares of RedHill Biopharma are set to reverse split before the market opens on Tuesday, August 20th. The 1-25 reverse split was announced on Friday, August 16th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, August 19th.
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
Further Reading
- Five stocks we like better than RedHill Biopharma
- What Are Dividend Challengers?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- MarketBeat Week in Review – 8/12 – 8/16
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.